Rivastigmine Patch

DRUG6 trials

Sponsors

NYU Langone Health, Seoul National University Hospital, Dong-A University, Novartis Pharmaceuticals, Chung-Ang University Hosptial, Chung-Ang University College of Medicine

Conditions

Alzheimer's DiseaseDeliriumMild to Moderate Alzheimer's DiseasePostoperative Cognitive Dysfunction

Phase 3

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

CompletedNCT01399125

Novartis PharmaceuticalsAlzheimer's Disease

Start: 2011-07-31End: 2013-05-31Updated: 2014-08-04

Phase 4

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

CompletedNCT00835159

NYU Langone HealthDelirium, Postoperative Cognitive Dysfunction

Start: 2008-12-31End: 2010-10-31Updated: 2015-02-09

Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.

CompletedNCT02413554

Chung-Ang University Hosptial, Chung-Ang University College of MedicineDelirium

Start: 2013-04-30End: 2015-04-30Updated: 2015-04-10

NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.

CompletedNCT02703636

Novartis PharmaceuticalsMild to Moderate Alzheimer's Disease

Start: 2016-05-09End: 2018-05-07Updated: 2019-09-12

Unknown Phase

Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

CompletedNCT01312363

Seoul National University HospitalAlzheimer's Disease

Start: 2009-06-30End: 2011-07-31Updated: 2016-05-04

Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

CompletedNCT01380288

Dong-A UniversityAlzheimer's Disease

Start: 2011-06-30End: 2017-12-31Updated: 2018-02-05

Related Papers

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer’s dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial

PLoS ONE2017-08-0711 citations